Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | MMP8 | P22894 | 8/20 | 0.40 |
| ▸ | MMP3 | P08254 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842689 | 0.93 | MMP8 (0.39) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4845030 | 0.93 | ALDH1A1 (0.40) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4844870 | 0.92 | MAPT (0.42) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4840536 | 0.92 | MMP8 (0.45) | MMP8MMP3ALDH1A1NPSR1PTGER3 | |
| SCHEMBL1043997 | 0.92 | MMP8 (0.45) | MMP8MMP3ALDH1A1NPSR1PTGER3 | |
| SCHEMBL4842258 | 0.91 | CA12 (0.40) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4833948 | 0.91 | MMP8 (0.43) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4837224 | 0.91 | HCRTR1 (0.37) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4838206 | 0.91 | CA12 (0.40) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4840519 | 0.91 | MMP8 (0.44) | MMP8MMP3ALDH1A1NPSR1PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | CA12 4875/4885CA1 4641/4885CA2 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.